Cilostazol versus aspirin for secondary prevention of vascular events after stroke

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Kamal, Ayeesha K ^a   Naqvi, Imama ^a   Husain, Muhammad R ^a   Khealani, Bhojo A ^a   Saleheen, Danish ^b  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; PHOSPHODIESTERASE INHIBITOR;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 77950138454     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008076     Document Type: Review

References (17)

1. Algra 1996 Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. Journal of Neurology, Neurosurgery and Psychiatry 1996;60(2):197-99.
2. Burke 1995 Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, et al.Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26(3):386-91.
3. Elam 1998 Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, DavidsonM, et al.Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscleriosis, Thrombosis, and Vascular Biology 1998;18(12): 1942-7.
4. Feldmann 1990 Feldmann E, Daneault N, Kwan E, Ho KJ, Pessin MS, Langenberg P, et al.Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990;40(10):1541-5.
5. Huang 2008 Huang Y, Cheng Y,Wu J, Li Y, Xu E, Hong Z, et al.Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, doubleblind, pilot study. Lancet Neurology 2008;7(6):494-9.
6. Ikeda 1999 Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thrombosis and Haemostasis 1999;82(2): 435-8.
7. Inoue 1999 Inoue T, Sohma R, Morooka S. Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thrombosis Research 1999;93(3): 137-43.
8. Kayanoki 1997 Kayanoki Y, Che W, Kawata S, Matsuzawa Y, Higashiyama S, Taniguchi N. The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells. Biochemica and Biophysical Research Communications 1997;238(2):478-81.
9. Liu 2000 Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemiainduced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. Journal of Cardiovascular Pharmacology 2000;36(3): 351-60.
10. Liu 2007 Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurology 2007;6(5):456-64.
11. Lopez 2006 Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367 (9524):1747-57.
12. Matsumoto 2005 Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atherosclerosis Supplements 2005;6(4):33-40.
13. Minami 1997 Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, et al.Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sciences 1997;61(25): 383-9.
14. Nishio 1997 Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Hormone and Metabolic Research 1997;29(10):491-5.
15. Rother 2008 Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, et al.Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovascular Diseases 2008;25(4):366-74.
16. Shinohara 2008 Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, et al.Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovascular Diseases 2008;26(1):63- 70.
17. Wong 2002 Wong KS, Li H, LamWW, Chan YL, Kay R. Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke 2002;33(2):532-6.